- Applied Energetics (OTCQB:AERG) has been granted two new patents, bolstering its advanced laser technology portfolio.
- The patents focus on disrupting hypersonic vehicles and pathogen detection and neutralization technologies.
- AERG’s portfolio now includes 27 issued patents, highlighting its strategic growth in defense and commercial applications.
Applied Energetics, Inc. (OTCQB:AERG), a prominent developer of advanced laser and optical technologies, has announced the issuance of two new patents by the United States Patent and Trademark Office (USPTO). These patents, U.S. Patent No. 12,171,055 and U.S. Patent No. 12,320,702, are pivotal in solidifying the company's leadership in laser systems for aerospace, defense, and commercial sectors.
Patent No. 12,171,055, issued on December 17, 2024, titled "Pulsed Laser Thermal Excitation," details innovative methods to generate range-specific thermal plasma using an ultrashort pulse laser, a significant capability that facilitates the disruption of high-speed objects like hypersonic vehicles. Meanwhile, Patent No. 12,320,702, issued on June 3, 2025, is focused on "Pathogen Detection and Neutralization Using Deep UV-C Generation Via Seeded Raman Amplification and Second Harmonic Generation," offering a tunable UV-C pulsed light system for pathogen detection and neutralization.
Dr. Stephen McCahon, Chief Science Officer and Co-founder of Applied Energetics, highlighted that these patents mark significant advancements in ultrashort pulsed laser applications, reinforcing the company's mission to provide high-performance solutions to meet evolving defense needs. Chris Donaghey, CEO, emphasized that the expanded patent portfolio strengthens AERG's competitive edge, fostering new collaboration and commercialization opportunities.
These recent additions bring the total number of Applied Energetics' issued patents to 27, with the company continuing to prioritize research and development in defense, aerospace, and industrial markets. The organization’s proprietary laser technologies aim to deliver enhanced national security capabilities and have potential applications in commercial markets.
